Factors Associated with Chronic Hepatitis C Direct-acting Antiviral Prescriptions in Maine

Authors

Colin T. Waters, Maine Medical Center
Anya K. Cutler, Maine Medical Center
Kinna Thakarar, Division of Infectious Diseases, Maine Medical Center, Portland, Maine, USA.
Kathleen Fairfield, Department of Internal Medicine, Maine Medical Center, Portland, Maine, USA.

Files

Description

Introduction -2.5 to 4.7 million people in the United States have active Hepatitis C (HCV) infections. •Chronic HCV infection is linked to substantial morbidity including cirrhosis and liver failure. •Oral direct-acting antivirals (DAA) yield sustained virologic response in 90 to 95% of individuals. •Many patients eligible for DAA therapy have not received treatment.

Publication Date

4-26-2022

Publisher

Maine Medical Center

City

Portland, Maine

Disciplines

Medical Education

Comments

2022 Lambrew Retreat

Recommended Citation

Waters, Colin T.; Cutler, Anya K.; Thakarar, Kinna; and Fairfield, Kathleen, "Factors Associated with Chronic Hepatitis C Direct-acting Antiviral Prescriptions in Maine" (2022). Costas T. Lambrew Research Retreat 2022. 22.
https://knowledgeconnection.mainehealth.org/lambrew-retreat-2022/22